Biofrontera Completes Sale of Xepi US License

The latest announcement is out from Biofrontera ( (BFRI) ).

On November 6, 2025, Biofrontera Inc. completed the sale of its US license for Xepi® (ozenoxacin) Cream to Pelthos Therapeutics Inc. for up to $10 million. The transaction, which includes an initial $3 million payment and potential milestone payments, aims to strengthen Biofrontera’s cash position and support the growth of its photodynamic therapy platform, particularly the expansion of Ameluz® into additional indications. This strategic move is expected to fund the company to profitability and allows Biofrontera to focus on its core PDT franchise.

The most recent analyst rating on (BFRI) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Biofrontera stock, see the BFRI Stock Forecast page.

Spark’s Take on BFRI Stock

According to Spark, TipRanks’ AI Analyst, BFRI is a Neutral.

Biofrontera’s overall score is driven by strong technical momentum and positive earnings call sentiment, offset by weak financial performance and valuation concerns. The company’s strategic shifts and growth prospects are promising, but profitability and cash flow challenges remain significant risks.

To see Spark’s full report on BFRI stock, click here.

More about Biofrontera

Biofrontera Inc. is a U.S.-based biopharmaceutical company specializing in the development and treatment of dermatological conditions, with a focus on photodynamic therapy (PDT). The company commercializes the drug-device combination Ameluz® with the RhodoLED® lamp series for PDT of actinic keratosis, pre-cancerous skin lesions that may progress to invasive skin cancers. Biofrontera also conducts clinical trials to extend the use of its products to treat non-melanoma skin cancers and moderate to severe acne.

Average Trading Volume: 185,909

Technical Sentiment Signal: Buy

Current Market Cap: $11.63M

Learn more about BFRI stock on TipRanks’ Stock Analysis page.